Edgewise Therapeutics, Inc. (EWTX) Cash and securities
- Total cash · latest quarter (USD): Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | (m) | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 72.32M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $72.32M | (m) | (m) |
| 2026-03-31 | (m) | (m) | $33.21M | (m) | (m) |
| 2025-12-31 | (m) | (m) | $61.15M | (m) | (m) |
| 2025-09-30 | (m) | (m) | $46.00M | (m) | (m) |
| 2025-06-30 | (m) | (m) | $43.40M | (m) | (m) |
| 2025-03-31 | (m) | (m) | $49.92M | (m) | (m) |
| 2024-12-31 | (m) | (m) | $41.67M | (m) | (m) |
| 2024-09-30 | (m) | (m) | $44.81M | (m) | (m) |
| 2024-06-30 | (m) | (m) | $43.48M | (m) | (m) |
| 2024-03-31 | (m) | (m) | $30.26M | (m) | (m) |
| 2023-12-31 | (m) | (m) | $86.10M | (m) | (m) |
| 2023-09-30 | (m) | (m) | $32.96M | (m) | (m) |
| 2023-06-30 | (m) | (m) | $31.81M | (m) | (m) |
| 2023-03-31 | (m) | (m) | $48.23M | (m) | (m) |
| 2022-12-31 | (m) | (m) | $21.99M | (m) | (m) |
| 2022-09-30 | (m) | (m) | $109.75M | (m) | (m) |
| 2022-06-30 | (m) | (m) | $18.34M | (m) | (m) |
| 2022-03-31 | (m) | (m) | $34.45M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $15.57M | (m) | (m) |
| 2021-09-30 | (m) | (m) | $10.57M | (m) | (m) |
| 2021-06-30 | (m) | (m) | $50.40M | (m) | (m) |
| 2021-03-31 | (m) | (m) | $221.04M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $104.92M | (m) | (m) |
| 2020-09-30 | (m) | (m) | $38.73M | (m) | (m) |
| 2020-06-30 | (m) | (m) | $16.87M | (m) | (m) |
| 2020-03-31 | (m) | (m) | $20.91M | (m) | (m) |
| 2019-12-31 | (m) | (m) | $23.65M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |